β¨ Medicines Notices
18 MAY 2006
NEW ZEALAND GAZETTE, No. 46
1179
Health
Medicines Act 1981
Revocation of Consent to the Distribution of a New Medicine
In the notice published in the New Zealand Gazette, 23 March 2006, No. 27, page 723, under the heading Consent to the Distribution of New Medicines, the entries for Arabloc 10mg film coated tablet, Arabloc 100mg film coated tablet, Arabloc 20mg film coated tablet are revoked.
Dated this 14th day of May 2006.
KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go3304
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the schedule hereto:
Schedule
Product: Arabloc
Active Ingredient: Leflunomide 10mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Aventis Intercontinental, Compeigne, France
Note: This consent is valid for two years from 23 March 2006.
Product: Arabloc
Active Ingredient: Leflunomide 100mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Aventis Intercontinental, Compeigne, France
Note: This consent is valid for two years from 23 March 2006.
Product: Arabloc
Active Ingredient: Leflunomide 20mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Aventis Intercontinental, Compeigne, France
Note: This consent is valid for two years from 23 March 2006.
Dated this 14th day of May 2006.
KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go3303
Renewal of Provisional Consent to the Distribution of New Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Amyl Nitrite Inhalant
Active Ingredient: Amyl nitrite 98%w/v
Dosage Form: Volatile liquid for inhalation
New Zealand Sponsor: Baxter Healthcare Limited
Manufacturer: James Alexander Corporation, Blairstown, New Jersey, United States of America
Note: This consent is valid for two years from 7 August 2005.
Product: Arava
Active Ingredient: Leflunomide 10mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Aventis Pharma Pty Limited
Manufacturer: Aventis Intercontinental, Compeigne, France
Note: This consent is valid for two years from 23 March 2006.
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2006, No 46
Gazette.govt.nz —
NZ Gazette 2006, No 46
β¨ LLM interpretation of page content
π₯ Revocation of Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare14 May 2006
Medicines Act 1981, Revocation, Consent, Distribution, Arabloc
- KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001)
π₯ Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare14 May 2006
Medicines Act 1981, Provisional Consent, Distribution, Arabloc, Leflunomide
- KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001)
π₯ Renewal of Provisional Consent to the Distribution of New Medicines
π₯ Health & Social Welfare14 May 2006
Medicines Act 1981, Renewal, Provisional Consent, Distribution, Amyl Nitrite Inhalant, Arava, Leflunomide
- KAREN MITCHELL, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001)